Hypercholesterolemia abrogates remote ischemic preconditioning-induced cardioprotection: Role of reperfusion injury salvage kinase signals

Shock

Volumn 47, Issue 3, 2017, Pages 363-369

  Ma, Lei Lei ^a,b   Kong, Fei Juan ^b,c   Guo, Jun Jie ^d   Zhu, Jian Bing ^a   Shi, Hong Tao ^a   Li, Yang ^a   Sun, Ren Hua ^b   Ge, Jun Bo ^a  

^a FUDAN UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d QINGDAO UNIVERSITY   (China)

Author keywords

Cardioprotection; GSK3 ; hypercholesterolemia; remote ischemic preconditioning

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; CASPASE 3; CHOLESTEROL; GLYCOGEN SYNTHASE KINASE 3BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MG53 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN KINASE B; PROTEIN P85; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WORTMANNIN; ANDROSTANE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HEART INFARCTION SIZE; HEART MUSCLE NECROSIS; HEART PROTECTION; HYPERCHOLESTEROLEMIA; IMMUNOBLOTTING; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; TUNEL ASSAY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; COMPLICATION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANDROSTADIENES; ANIMALS; APOPTOSIS; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HYPERCHOLESTEROLEMIA; ISCHEMIC PRECONDITIONING; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84983504681     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000737     Document Type: Article

References (39)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349:1498-1504, 1997.
2. Murphy E, Steenbergen C: Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88:581-609, 2008.
3. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, et al.: Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382:597-604, 2013.
4. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P: Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87:893-899, 1993.
5. Li J, Xuan W, Yan R, Tropak MB, Jean-St-Michel E, Liang W, Gladstone R, Backx PH, Kharbanda RK, Redington AN: Remote preconditioning provides potent cardioprotection via PI3K/Akt activation and is associated with nuclear accumulation of b-catenin. Clin Sci (Lond) 120:451-462, 2011.
6. Heidbreder M, Naumann A, Tempel K, Dominiak P, Dendorfer A: Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways. Cardiovasc Res 78:108-115, 2008.
7. Heinen NM, Pütz VE, Görgens JI, Huhn R, Grüber Y, Barthuber C, Preckel B, Pannen BH, Bauer I: Cardioprotection by remote ischemic preconditioning exhibits a signaling pattern different from local ischemic preconditioning. Shock 36:45-53, 2011.
8. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, et al.: MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121:2565-2574, 2010.
9. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ: Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 104:1240-1252, 2009.
10. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA: New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. Ann N Y Acad Sci 947:181-195, 2001.
11. Osipov RM, Bianchi C, Feng J,ClementsRT, LiuY, RobichMP, Glazer HP, Sodha NR, Sellke FW: Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion. Circulation 120:S22-30, 2009.
12. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 66:1142-1174, 2014.
13. Balakumar P, Singh H, Singh M, Anand-Srivastava MB: The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res 60:18-23, 2009.
14. Drenger B, Ostrovsky IA, Barak M, Nechemia-Arbely Y, Ziv E, Axelrod JH: Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3-and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology 114: 1364-1372, 2011.
15. Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B: Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo. Br J Anaesth 97:298-306, 2006.
16. Zhang SZ, Wang NF, Xu J, Gao Q, Lin GH, Bruce IC, Xia Q: Kappa-opioid receptors mediate cardioprotection by remote preconditioning. Anesthesiology 105:550-556, 2006.
17. De Paulis D, Chiari P, Teixeira G, Couture-Lepetit E, Abrial M, Argaud L, Gharib A, Ovize M: Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart. Basic Res Cardiol 108:379, 2013.
18. Penumathsa SV, Thirunavukkarasu M, Koneru S, Juhasz B, Zhan L, Pant R, Menon VP, Otani H, Maulik N: Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 42:508-516, 2007.
19. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Ezetimibe Study Group: effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107:2409-2415, 2003.
20. Iliodromitis EK, Zoga A, Vrettou A, Andreadou I, Paraskevaidis IA, Kaklamanis L, Kremastinos DT: The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. Atherosclerosis 188:356-362, 2006.
21. Yu CK, Li YH, Wong GT, Wong TM, Irwin MG: Remifentanil preconditioning confers delayed cardioprotection in the rat. Br J Anaesth 99:632-638, 2007.
22. Byrne CJ, McCafferty K, Kieswich J, Harwood S, Andrikopoulos P, Raftery M, Thiemermann C, Yaqoob MM: Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation 125:1256-1265, 2012.
23. Mykytenko J, Kerendi F, Reeves JG, Kin H, Zatta AJ, Jiang R, Guyton RA, Vinten-Johansen J, Zhao ZQ: Long-term inhibition of myocardial infarction by postconditioning during reperfusion. Basic Res Cardiol 102:90-100, 2007.
24. Ma LL, GeHW, Kong FJ, Qian LB, Hu BC, Li Q, Xu L, Liu JQ, Xu YX, Sun RH: Ventricular hypertrophy abrogates intralipid-induced cardioprotection by alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3b signal. Shock 41:435-442, 2014.
25. Ma L, Kong F, Ge H, Liu J, Gong F, Xu L, Hu B, Sun R: Ventricular hypertrophy blocked delayed anesthetic cardioprotection in rats by alteration of iNOS/COX-2 signaling. Sci Rep 4:7071, 2014.
26. Ma LL, Zhang FJ, Kong FJ, Qian LB, Ma H, Wang JA, Yan M: Hypertrophied myocardium is refractory to sevoflurane-induced protection with alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3b signals. Shock 40:217-221, 2013.
27. Zhao H, Wang Y, Wu Y, Li X, Yang G, Ma X, Zhao R, Liu H: Hyperlipidemia does not prevent the cardioprotection by postconditioning against myocardial ischemia/reperfusion injury and the involvement of hypoxia inducible factor-1alpha upregulation. Acta Biochim Biophys Sin (Shanghai) 41:745-753, 2009.
28. Roach PD, Balasubramaniam S, Hirata F, Abbey M, Szanto A, Simons LA, Nestel PJ: The low-density lipoprotein receptor and cholesterol synthesis are affected differently by dietary cholesterol in the rat. Biochim Biophys Acta 1170:165-172, 1993.
29. Horton JD, Cuthbert JA, Spady DK: Regulation of hepatic 7 alpha-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem 270:5381-5387, 1995.
30. Gorbe A, Varga ZV, Kupai K, Bencsik P, Kocsis GF, Csont T, Boengler K, Schulz R, Ferdinandy P: Cholesterol diet leads to attenuation of ischemic preconditioning-induced cardiac protection: the role of connexin 43. Am J Physiol Heart Circ Physiol 300:H1907-1913, 2011.
31. Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, Marais deW, Csont T, Ferdinandy P: Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 297:H1729-1735, 2009.
32. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P: Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 316: 154-161, 2006.
33. Wang TD, Chen WJ, Su SS, Lo SC, LinWW, Lee YT: Increased cardiomyocyte apoptosis following ischemia and reperfusion in diet-induced hypercholesterolemia: relation to Bcl-2 and Bax proteins and caspase-3 activity. Lipids 37:385-394, 2002.
34. Okamura T, Miura T, Takemura G, Fujiwara H, Iwamoto H, Kawamura S, Kimura M, Ikeda Y, Iwatate M, Matsuzaki M: Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemiareperfused rat heart. Cardiovasc Res 45:642-650, 2000.
35. Gustafsson AB, Gottlieb RA: Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol 292:C45-51, 2007.
36. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104:3046-3051, 2001.
37. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, Li J, Gross G, Wilson GJ, Callahan J, et al.: Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 117:191-200, 2009.
38. Jin RL, Li WB, Li QJ, Zhang M, Xian XH, Sun XC, Zhao HG, Qi J: The role of extracellular signal-regulated kinases in the neuroprotection of limb ischemic preconditioning. Neurosci Res 55:65-73, 2006.
39. Wang X, XieW, Zhang Y, Lin P, Han L, Han P,Wang Y, Chen Z, Ji G, ZhengM, et al.: Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res 107:76-83, 2010.